Chylomicronemia due to LPL inhibitor
Okubo, M.
Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 3): 32-33
2001
ISSN/ISBN: 0047-1852 PMID: 11347085 Document Number: 534358
Document emailed within 1 workday
Related Documents
Nikitin, Y.P.; Makarenkova, K.V.; Malutina, S.K.; Scherbakova, L.V.; Ivanova, M.V. 2013: The chylomicronemia under interpretation of the results of detection of lipid profile of blood Klinicheskaia Laboratornaia Diagnostika 7: 38-41Laurell, M.; Stenflo, J. 1989: Protein C inhibitor from human plasma: characterization of native and cleaved inhibitor and demonstration of inhibitor complexes with plasma kallikrein Thrombosis and Haemostasis 62(3): 885-891
Khan, N.A.; Havouis, R.; Quemener, V.; Moulinoux, J.P. 1992: Protein kinase C inhibitor (H-7) potentiates antiproliferative effects of a polyamine biosynthesis inhibitor Anticancer Research 12(4): 1223-1226
Depré, M.; Van Hecken, A.; Verbesselt, R.; De Lepeleire, I.; Schwartz, J.; Porras, A.; Larson, P.; Lin, C.; De Schepper, P.J. 1998: Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man International Journal of Clinical Pharmacology Research 18(2): 53-61
Bolten, W.W. 2003: In high risk patients cyclooxygenase inhibitor plus proton pump inhibitor MMW Fortschritte der Medizin 145(5): 9
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
Tourbaf, K.D.; Dunlap, B.E.; Ambrus, J.L.; Rodman, D.J.; Atwal, A.J. 1982: The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia a patient with inhibitor Journal of Medicine 13(5-6): 399-410
Sills, T.; Heptinstall, S. 1986: Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour Thrombosis and Haemostasis 55(3): 305-308
Błach-Olszewska, Z.; Wrześniowska, U. 1986: Inhibitor of physiological interferon synthesis. I. Isolation, physiochemical and biological properties of crude inhibitor preparations Archivum Immunologiae et Therapiae Experimentalis 34(5-6): 533-540
Kakinuma, Y.; Miyauchi, T. 2001: Endothelin receptor antagonist, phosphodiesterase inhibitor, thromboxane inhibitor Nihon Rinsho. Japanese Journal of Clinical Medicine 59(6): 1139-1144
Tamura, M.; Konishi, F.; Inagami, T. 1993: A novel endogenous sodium-pump inhibitor in pig urine: purification and comparison with the inhibitor purified from bovine adrenal glands Journal of Cardiovascular Pharmacology 22(Suppl 2): S47-S50
Due, C.; Ebbesen, P. 1981: Mouse skin beta-irradiated 3 months earlier shows increased content of a 30-50,000 MW mitotic inhibitor and decreased susceptibility to an exogenous inhibitor Anticancer Research 1(2): 87-88
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Voloshina, E.I. 1978: Determination of the oil-soluble salt of cyclohexylamine (inhibitor M-1) and cyclohexylamine metanitrobenzoate (inhibitor Ts-2) in air by a thin-layer chromatographic method Gigiena i Sanitariia 8: 72-74
Caputo, R.P.; Giambartolomei, A.; Simons, A.; Reger, M.; Wagner, S.; Esente, P. 2001: Adjunctive therapies in the cath lab. use of combination glycoprotein IIb/IIIa inhibitor and direct thrombin inhibitor drugs to support percutaneous coronary stent placement in a patient with renal insufficiency and heparin-induced thrombocytopenia Journal of Invasive Cardiology 13(9): 657-660
Joo, K.M.; Song, S.Y.; Park, K.; Kim, M.H.; Jin, J.; Kang, B.G.; Jang, M.J.; Lee, G.S.; Kim, M.S.; Nam, D.-H. 2008: Response of brain specific microenvironment to P-glycoprotein inhibitor: an important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors International Journal of Oncology 33(4): 705-712
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Fukuda, C.; Iijima, K.; Inoue, N.; Takashima, Y.; Urabe, C.; Nakamura, K. 1988: Clinical evaluation of alpha 2 plasmin inhibitor and alpha 2 plasmin inhibitor-plasmin complex by enzyme immunoassay method--with special reference to accident surgery Rinsho Byori. Japanese Journal of Clinical Pathology 36(3): 346-350
Malkovský, M.; Asherson, G.L.; Chandler, P.; Colizzi, V.; Watkins, M.C.; Zembala, M. 1983: Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten- and I-J-driven liberation of an inhibitor of cell proliferation by Lyt-1-2+ cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1+2+-specific suppressor cells Journal of Immunology 130(2): 785-790
Sprengers, E.D.; Akkerman, J.W.; Jansen, B.G. 1986: Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood Thrombosis and Haemostasis 55(3): 325-329